Skip to main navigation
logo

Investor Relations

  • Overview
  • News & Events
    • News Releases
    • Scientific Conferences
    • Investor Calendar
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historical Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Corporate Governance
    • Governance Documents
    • Management
    • Board of Directors
    • Committee Composition
  • Financials & Filings
    • SEC Filings
    • Annual Reports & Proxies
    • Quarterly Results
  • IR Resources
    • FAQs
    • Email Alerts
    • Contact IR

Event Details

Key Opinion Leader Event

Nov 8, 2021 10:30 AM EST

Galecto will host a key opinion leader event to discuss the current treatment landscape for NSCLC, as well as the potential for GB1211, Galecto’s galectin-3 inhibitor that is expected to enter a phase 2 trial in 1H 2022.

Listen to Webcast

Supporting Materials

Galecto Expert Perspectives: GB1211: A Potential Treatment for Non-Small Cell Lung Cancer 11.2 MB
Listen to recording 62.8 MB

Site - Investor Tools

  • Email Alerts
  • Print Page
  • RSS Feeds
  • Contact IR

© 2024 Galecto All rights reserved.

  • Cookies
  • Privacy Policy